[go: up one dir, main page]

PE20000381A1 - Nuevas formulaciones de paroxetina - Google Patents

Nuevas formulaciones de paroxetina

Info

Publication number
PE20000381A1
PE20000381A1 PE1998001126A PE00112698A PE20000381A1 PE 20000381 A1 PE20000381 A1 PE 20000381A1 PE 1998001126 A PE1998001126 A PE 1998001126A PE 00112698 A PE00112698 A PE 00112698A PE 20000381 A1 PE20000381 A1 PE 20000381A1
Authority
PE
Peru
Prior art keywords
paroxetine
presented
solid
semi
refers
Prior art date
Application number
PE1998001126A
Other languages
English (en)
Inventor
Ghazawi Ahmad
Leonard Graham Stanley
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of PE20000381A1 publication Critical patent/PE20000381A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION QUE SE PRESENTA EN FORMA DE CAPSULA QUE CONTIENE 1)PAROXETINA O LA BASE LIBRE O EL HEMIHIDRATO O EL ANHIDRATO DEL HIDROCLORURO O HIDROCLORURO AMORFO O ANHIDRATO CRISTALINO; 2)VEHICULO QUE SE PUEDEN PRESENTAR COMO a)LIQUIDO FLUIBLE O LIQUIDO VISCOSO O SEMISOLIDO O GEL; b)SOLIDO O SEMISOLIDO COMO CERAS Y GRASAS NATURALES O SINTETICAS; c)POLIMEROS QUE FORMAN PELICULAS O TERMOPLASTICOS; 3)EXCIPIENTES HIDROFOBOS O ANHIDROS. LA COMPOSICION TAMBIEN SE PUEDE PRESENTAR EN FORMA DE TABLETAS, PERLAS, ESFERULAS, GRANULOS, PASTILLAS O GELES; QUE PUEDE ESTAR REVESTIDA PARA RETARDAR O CONTROLAR LA LIBERACION DE PAROXETINA O PARA ENMASCARAR EL SABOR O PARA FACILITAR SU ADMINISTRACION. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. LA PAROXETINA ES UTIL PARA EL TRATAMIENTO Y PROFILAXIS DE DEPRESION, TRASTORNO COMPULSIVO OBSESIVO Y PANICO
PE1998001126A 1997-11-21 1998-11-18 Nuevas formulaciones de paroxetina PE20000381A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9724544.3A GB9724544D0 (en) 1997-11-21 1997-11-21 Novel Formulation

Publications (1)

Publication Number Publication Date
PE20000381A1 true PE20000381A1 (es) 2000-05-07

Family

ID=10822374

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998001126A PE20000381A1 (es) 1997-11-21 1998-11-18 Nuevas formulaciones de paroxetina

Country Status (24)

Country Link
EP (1) EP1033986A1 (es)
JP (1) JP2001523718A (es)
KR (1) KR20010032320A (es)
CN (1) CN1279608A (es)
AP (1) AP2000001821A0 (es)
AR (1) AR015485A1 (es)
AU (1) AU1168099A (es)
BG (1) BG104527A (es)
BR (1) BR9814220A (es)
CO (1) CO4970832A1 (es)
DZ (1) DZ2658A1 (es)
EA (1) EA200000552A1 (es)
GB (1) GB9724544D0 (es)
HU (1) HUP0100580A3 (es)
IL (1) IL136106A0 (es)
MA (1) MA24704A1 (es)
NO (1) NO20002590L (es)
OA (1) OA11385A (es)
PE (1) PE20000381A1 (es)
PL (1) PL340555A1 (es)
SK (1) SK7342000A3 (es)
TR (1) TR200001423T2 (es)
WO (1) WO1999026625A1 (es)
ZA (1) ZA9810637B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9810180D0 (en) * 1998-05-13 1998-07-08 Smithkline Beecham Plc Novel formulation
ATE311883T1 (de) 1999-03-12 2005-12-15 Aesica Pharmaceuticals Ltd Stabile pharmazeutische anwendungsform für paroxetin-anhydrat
CA2341984A1 (en) 1999-07-01 2001-01-11 Paolo Mascagni Complexes of paroxetine, with cyclodextrines or cyclodextrin derivatives
DE19930454A1 (de) * 1999-07-02 2001-01-04 Knoll Ag Feste Paroxetin enthaltende Zubereitungen
US6720003B2 (en) 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
US7011846B2 (en) * 2001-12-21 2006-03-14 Shire Laboratories, Inc. Oral capsule formulation with increased physical stability
SE0200475D0 (sv) * 2002-02-15 2002-02-15 Ltp Lipid Technologies Provide Oral farmaceutisk beredning
WO2006119779A2 (en) * 2005-05-10 2006-11-16 Lifecycle Pharma A/S A pharmaceutical composition comprising an aldosterone antagonist in form of solid solution
US20120322752A1 (en) * 2009-12-08 2012-12-20 Sung Kyun Lee SOLID DISPERSIONS CONTAINING 20-O-beta-D-GLUCOPYRANOSYL-20(S)-PROTOPANAXADIOL
GB201020032D0 (en) * 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
CN103961333B (zh) * 2014-05-07 2020-02-21 浙江华海药业股份有限公司 甲磺酸帕罗西汀胶囊及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9707585A (es) * 1995-04-03 1997-12-31 Abbott Lab Mezclas homogeneas de farmacos y aditivos de fusion a baja temperatura para liberacion controlada.
SK95099A3 (en) * 1997-01-15 2000-01-18 Smithkline Beecham Plc Process for the preparation of free-flowing form of paroxetine hydrochloride, pharmaceutical composition containing same and use thereof

Also Published As

Publication number Publication date
GB9724544D0 (en) 1998-01-21
TR200001423T2 (tr) 2000-10-23
HUP0100580A3 (en) 2002-05-28
MA24704A1 (fr) 1999-07-01
PL340555A1 (en) 2001-02-12
SK7342000A3 (en) 2000-12-11
BR9814220A (pt) 2001-12-26
KR20010032320A (ko) 2001-04-16
AU1168099A (en) 1999-06-15
CN1279608A (zh) 2001-01-10
IL136106A0 (en) 2001-05-20
AR015485A1 (es) 2001-05-02
DZ2658A1 (fr) 2003-03-22
AP2000001821A0 (en) 2000-06-30
BG104527A (en) 2001-04-30
OA11385A (en) 2004-01-27
WO1999026625A1 (en) 1999-06-03
NO20002590L (no) 2000-07-19
HUP0100580A2 (hu) 2002-04-29
ZA9810637B (en) 2000-05-22
JP2001523718A (ja) 2001-11-27
CO4970832A1 (es) 2000-11-07
NO20002590D0 (no) 2000-05-19
EP1033986A1 (en) 2000-09-13
EA200000552A1 (ru) 2000-10-30

Similar Documents

Publication Publication Date Title
ES2037082T3 (es) Una composicion para la liberacion controlada de un farmaco.
PE20000381A1 (es) Nuevas formulaciones de paroxetina
RU94032150A (ru) Лекарственное средство с замедленным высвобождением активно-действующего вещества
ES2201361T3 (es) Formulacion topica que contiene un tampon fosfato con estimulador de la permeabilidad cutanea.
ES2178430T3 (es) Utilizacion de composiciones farmaceuticas gelificables en parodontologia.
ES2189868T3 (es) Microesferas y nanoesferas biodegradables de liberacion controlada que contienen ciclosporina.
BR0012869A (pt) Forma de dosagem farmacêutica de componentes múltiplos
ATE248589T1 (de) Matrix zur gesteuerten freisetzung von arzneistoffen
ES2156198T3 (es) Composiciones para envoltorios de capsulas, y utilizacion de las mismas.
ES2187822T3 (es) Comprimidos de disgregacion rapida.
PT93170A (pt) Processo para a preparacao de dispositivos distribuidores nomeadamente de capsulas contendo um ingrediente activo
CO4600739A1 (es) Formulaciones liquidas orales a base de alendronato
AR013947A1 (es) Composicion farmaceutica para combinacion de piperidinoalcanol- descongestionante
PT797991E (pt) Formulacao com libertacao prolongada contendo venlafaxina
AR022085A1 (es) Una forma de dosificacion farmaceutica de liberacion sostenida y una tableta comprimida
PT1028707E (pt) Formulacoes oftalmicas de libertacao controlada contendo medicamentos soluveis em agua
ES2158101T3 (es) Formulaciones farmaceuticas efervescentes que contienen microcapsulas biodegradables de liberacion controlada.
AU1810783A (en) Constant release tablet formulation
ES2128369T3 (es) Procedimiento para la fabricacion de formas farmaceuticas solidas con liberacion prolongada en dos etapas.
UA42061C2 (uk) Фармацевтична композиція для перорального введення, що містить інгібітори протонного насоса
IS4083A (is) Samsetning lyfjaefna, aðferð til framleiðslu hennar, og notkunar sem lyfja
ATE517615T1 (de) Schmerzstillendes und entzündungshemmendes pflaster zur lokalen anwendung
ATE396712T1 (de) Pharmazeutische zubereitung zur modifizierten freisetzung
KR960700061A (ko) 니코틴 의존상태 치료를 위한 약리학적 제형 (pharmaceutical composition for treating nicotine dependence)
ATE230993T1 (de) Pharmazeutische zusammensetzung zur behandlung von alkoholabhängigkeit, die opioid antagonisten mit nmda-rezeptorkomplex-modulatoren enthält

Legal Events

Date Code Title Description
FC Refusal